Action BHC BAUSCH HEALTH COMPANIES INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Bausch Health Companies Inc. Toronto S.E.

Actions

BHC

CA0717341071

Marché Fermé - Toronto S.E.
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
10,32 CAD +2,89% Graphique intraday de Bausch Health Companies Inc. +5,20% -2,92%
21/06 Bausch Health poursuit Norwich en contrefaçon de brevet pour une demande de version générique d'un médicament contre le syndrome de l'intestin irritable MT
23/05 Bausch Health annonce l'élargissement de la couverture du régime public d'assurance-médicaments pour Uceris au Canada MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada
Bausch Health Companies - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich
Bausch Health Companies Inc. Approves Directorate Appointments
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters
RBC Noes Bausch Health Filing For Rehearing in Appellate Court
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform
Bausch Health Announces First Quarter 2024 Results
Bausch Health Shares Fall Following Q1 Results
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance
Bausch: Q1 Earnings Snapshot
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BHC
  4. Action BHC
  5. Actualités Bausch Health Companies Inc.
  6. Autres langues